Dx&Vx is a company focused on developing innovative products and services in the fields of microbiome, healthcare, diagnostics, and new drugs. They aim to improve health outcomes through cutting-edge research and collaboration. Their pipeline includes various products and services designed to address health challenges with advanced technological solutions.
The order this company entered each market โ oldest to newest
Avixgen signs $360M drug delivery tech deal
Avixgen signs $360M licensing deal for drug delivery platform
Sign up to see the full signal feed
How Dx & Vx's international expansion compares to its competitors
Dx & VxYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Dx & VxYou | 0 | 0 | 0% | 0 | 63 |
RA Manager
View postingSeoul, South Korea ยท last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Multiple Korean companies reported Q2 2025 financial results, including Kiwoom Securities, SOOP, GS E&C, and others. Several firms announced investments, contracts, and corporate actions.
DXVX's personalized health supplement service Helsner won the grand prize in the mobile web service health category at the 2024 Web Award Korea.
COREE and Italian partners identified microbiome biomarkers for diabetes and obesity, presenting findings at EHMSG workshop in Rome.
Unlock verified emails & direct dials
Free ยท No credit card needed
Quick answers about Dx & Vx's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams fullโmarket visibility.โ
ยฉ 2026 Pubrio. All rights reserved.
